Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 31:13:17562872211039034.
doi: 10.1177/17562872211039034. eCollection 2021 Jan-Dec.

Update on the management of overactive bladder

Christina Fontaine  1 , Emma Papworth  2 , John Pascoe  3 , Hashim Hashim  2
Affiliations
Review

Update on the management of overactive bladder

Christina Fontaine et al. Ther Adv Urol. .

Abstract

Overactive bladder (OAB) syndrome is a common condition characterised by urinary urgency, with or without urgency incontinence, frequency and nocturia, in the absence of any other pathology. Clinical diagnosis is based upon patient self-reported symptomology. Currently there is a plethora of treatments available for the management of OAB. Clinical guidelines suggest treatment via a multidisciplinary pathway including behavioural therapy and pharmacotherapy, which can be commenced in primary care, with referral to specialist services in those patients refractory to these treatments. Intradetrusor botulinum A and sacral neuromodulation provide safe and efficacious management of refractory OAB. Percutaneous tibial nerve stimulation and augmentation cystoplasty remain available and efficacious in a select group of patients. Unfortunately, there remains a high rate of patient dissatisfaction and discontinuation in all treatments and thus there remains a need for emerging therapies in the management of OAB.

Keywords: BOTOX; antimuscarinic; beta-agonist; overactive bladder; sacral neuromodulation; urinary incontinence.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

Figures

Figure 1.
Figure 1.
Comparison of NICE, EAU and AUA guidelines for the management of OAB.– AUA, American Urological Association; EAU, European Association of Urology; NICE, National Institute for Health and Care Excellence; OAB, overactive bladder; PTNS, posterior tibial nerve stimulation; SNM, sacral neuromodulation.
See this image and copyright information in PMC

Comment in

References

    1. Haylen BT, de Ridder D, Freeman RM, et al.. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 2010; 21: 5–26. - PubMed
    1. Milsom I, Abrams P, Cardozo L, et al.. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760–766. - PubMed
    1. Coyne KS, Margolis MK, Kopp ZS, et al.. Racial differences in the prevalence of overactive bladder in the United States from the epidemiology of LUTS (EpiLUTS) study. Urology 2012; 79: 95–101. - PubMed
    1. Coyne KS, Sexton CC, Bell JA, et al.. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn 2013; 32: 230–237. - PubMed
    1. Hu TW, Wagner TH, Bentkover JD, et al.. Estimated economic costs of overactive bladder in the United States. Urology 2003; 61: 1123–1128. - PubMed

LinkOut - more resources